Combination strategy

Combination strategy

A strategy in which a put and call with different strike prices and the same expiration are either both bought or both sold. Related: Straddle
Copyright © 2012, Campbell R. Harvey. All Rights Reserved.

Combination Strategy

An option strategy in which one buys or sells two options on the same underlying asset with the same expiration date but with different strike prices. A combination strategy allows one to profit from the difference in strike prices on or before the expiration date. See also: Spread, Straddle.
Farlex Financial Dictionary. © 2012 Farlex, Inc. All Rights Reserved
References in periodicals archive ?
"We look forward to working with Merck KGaA, Darmstadt, Germany and Pfizer to determine an appropriate combination strategy to help further improve outcomes for patients.
Although cost-effective, the SEDs-only strategy was dominated by a combination strategy of both SEDs and training.
The combination strategy can also be the combination of hands and facial expressions (e.g., wide opened eyes and raised eyebrows and hand covering mouth for intensification of surprise or shocked), or hand and head gesture (e.g., shaking head and waving hands for intensification of disinclination), or hands and shoulders (e.g., a shoulder shrug and open palms for intensification of 'I don't know').
Given previous results with standard therapy, enrollment in a clinical trial using a combination strategy was considered a reasonable option.
However, no matter what kinds of combination strategy are employed, the results have not varied a lot for one group of features and often remain in a certain range.
The Proposal is unclear as to critical elements of the combination strategy, integration and potential consequences for its stakeholders;
"Our take-home is that for patients who are at extremely high risk of fracture, combination strategy is a treatment strategy to be considered," said Dr.
Whether triple therapy or MTX + TNFi should be the preferred combination strategy for patients with active RA despite treatment with MTX alone continues to be a matter of debate."
The partnership is claimed to strengthen combination strategy in immuno-oncology, and underscore Merck KGaA, Darmstadt, Germany's science-driven approach to discovering and developing novel compounds through both internal capabilities and external collaborations.
It is well described that combination strategy with dual checkpoint inhibition has remarkably improved the outcomes of patients.
"This anti-PD-1 resistance-associated gene expression pattern defined a signature which was also detected across other common cancers of the lung, colon, kidney and pancreas." Understanding who is likely to respond or not will help determine which patients can be treated with anti-PD-1 or require a combination strategy. Dr.